Skip to main content
SpringerLink
Log in

Neoplastic meningitis: diagnosis and treatment considerations

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Neoplastic meningitis is an increasingly recognized complication of advanced metastatic cancer and, if left undiagnosed or untreated, is characterized by rapid neurologic deterioration and death. Thus, the diagnosis and treatment of neoplastic meningitis present challenges for the clinical oncologist. The diagnosis of neoplastic meningitis is based on clinical signs and symptoms, laboratory analysis of cerebrospinal fluid to determine cell count and cytology, and analysis of neuroimaging studies for evidence of leptomeningeal or cranial nerve enhancement. Once diagnosed, conventional treatment regimens may include radiotherapy combined with systemic or intrathecal chemotherapy, often with the antimetabolites cytarabine and/or methotrexate. However, the prognosis for neoplastic meningitis secondary to an underlying solid tumor or recurrent leukemia is poor with conventional treatment regimens. Therefore, novel agents for intrathecal administration, including DepoCytTM, mafosfamide, and topotecan, or novel therapeutic approaches, including conjugated monoclonal antibodies and immunotoxins or gene therapy, are currently under investigation. Such new agents and therapeutic approaches will facilitate the development of effective treatment strategies and will ultimately improve the outcome for patients with this devastating disease. This article provides an overview of the approaches to the diagnosis, evaluation, and treatment of neoplastic meningitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bleyer WA, Byrne TN. Leptomeningeal cancer in leukemia and solid tumors.Curr Probl Cancer 1988;12: 181–238.

    Article  CAS  PubMed  Google Scholar 

  2. Balm M, Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors.Arch Neurol 1996;53: 626–632.

    Article  CAS  PubMed  Google Scholar 

  3. Grove A. Meningeal carcinomatosis from a clinically undiagnosed early gastric cancer.Pathol Res Pract 1991;187: 341–345.

    Article  CAS  PubMed  Google Scholar 

  4. Honma K, Hamashima H. Fulminating gallbladder cancer presenting as leptomeningeal carcinomatosis and acute renal failure.Wien Klin Wochenschr 1990;102: 654–656.

    CAS  PubMed  Google Scholar 

  5. Ringenberg QS, Francis R, Doll DC. Meningeal carcinomatosis as the presenting manifestation of tumors of unknown origin.Acta Cytol 1990;34: 590–592.

    CAS  PubMed  Google Scholar 

  6. Leonardi Aet al. ‘Pure’ meningeal carcinomatosis as the autopsy-proven sole manifestation of an undetected cancer.Clin Neuropathol 1992;11: 60–63.

    CAS  PubMed  Google Scholar 

  7. Price RA, Johnson WW. The central nervous system in childhood leukemia. I. The arachnoid.Cancer 1973;31: 520–533.

    Article  CAS  PubMed  Google Scholar 

  8. Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A).Cancer 1970;26: 404–409.

    Article  CAS  PubMed  Google Scholar 

  9. Yap HY, Yap BS, Tashim CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer.Cancer 1978;42: 283–286.

    Article  CAS  PubMed  Google Scholar 

  10. Mayer R, Berkowitz R, Griffiths C. Central nervous system involvement by ovarian carcinoma: a complication of prolonged survival with metastatic disease.Cancer 1978;19: 318.

    Google Scholar 

  11. Nugent JLet al. CNS metastases in small cell bronchogenic carcinoma: increasing frequency and changing pattern with lengthening survival.Cancer 1979;44: 1885–1893.

    Article  CAS  PubMed  Google Scholar 

  12. Rosen STet al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience.Medicine (Baltimore) 1982;61: 45–53.

    Article  CAS  PubMed  Google Scholar 

  13. Bigner SH, Johnston WW. The cytopathology of cerebrospinal fluid. II. Metastatic cancer, meningeal carcinomatosis and primary central nervous system neoplasms.Acta Cytol 1981;25: 461–479.

    CAS  PubMed  Google Scholar 

  14. Boyle RT, Thomas M, Adam JH. Diffuse involvement of the leptomeninges by tumour—a clinical and pathological study of 63 cases.Postgrad Med J 1980;56: 149–158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Posner JB, Chernik NL. Intracranial metastases from systemic cancer.Adv Neurol 1978;19: 579–592.

    CAS  PubMed  Google Scholar 

  16. Aroney RS, Dalley DN, Chan WK, Bell DR, Levi JA. Meningeal carcinomatosis in small cell carcinoma of the lung.Am J Med 1981;71: 26–32.

    Article  CAS  PubMed  Google Scholar 

  17. Aisner J, Ostrow S, Govindan S, Wiernik PH. Leptomeningeal carcinomatosis in small cell carcinoma of the lung.Med Pediatr Oncol 1981;9: 47–59.

    Article  CAS  PubMed  Google Scholar 

  18. Littman Pet al. Soft-tissue sarcomas of the head and neck in children.Int J Radiat Oncol Biol Phys 1983;9: 1367–1371.

    Article  CAS  PubMed  Google Scholar 

  19. Meli FJ, Boccaleri CA, Manzitti J, Lylyk P. Meningeal dissemination of retinoblastoma: CT findings in eight patients.AJNR Am J Neuroradiol 1990;11: 983–986.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Trigg ME, Makuch R, Glaubiger D. Actuarial risk of isolated CNS involvement in Ewing's sarcoma following prophylactic cranial irradiation and intrathecal methotrexate.Int J Radiat Oncol Biol Phys 1985;11: 699–702.

    Article  CAS  PubMed  Google Scholar 

  21. Yu Let al. Isolated CNS involvement in Ewing's sarcoma.Med Pediatr Oncol 1990;18: 354–358.

    Article  CAS  PubMed  Google Scholar 

  22. Whelan HT, Sung JH, Mastri AR. Diffuse leptomeningeal gliomatosis: report of three cases.Clin Neuropathol 1987;6: 164–168.

    CAS  PubMed  Google Scholar 

  23. Civetello Let al. Leptomeningeal dissemination of low-grade gliomas in childhood.Neurology 1988;38: 562–566.

    Article  Google Scholar 

  24. Davila G, Duyckaerts C, Lazareth JP, Poisson M, Delattre JY. Diffuse primary leptomeningeal gliomatosis.J Neurooncol 1993;15: 45–49.

    Article  CAS  PubMed  Google Scholar 

  25. Ausman JIet al. Aggressive choroid plexus papilloma.Surg Neurol 1984;22: 472–476.

    Article  CAS  PubMed  Google Scholar 

  26. Deutsch M. The impact of myelography on the treatment results for medulloblastoma.Int J Radiat Oncol Biol Phys 1984;10: 999–1003.

    Article  CAS  PubMed  Google Scholar 

  27. Jennings MTet al. Neoplastic meningitis as the presentation of occult primitive neuroectodermal tumors.J Child Neurol 1993;8: 306–312.

    Article  CAS  PubMed  Google Scholar 

  28. Goldwein JWet al. Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas?Cancer 1991;67: 2766–2771.

    Article  CAS  PubMed  Google Scholar 

  29. Ross GW, Rubinstein LJ. Lack of histopathological correlation of malignant ependymomas with postoperative survival.J Neurosurg 1989;70: 31–36.

    Article  CAS  PubMed  Google Scholar 

  30. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis.Ann Neurol 1995;38: 51–57.

    Article  CAS  PubMed  Google Scholar 

  31. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.Cancer 1982;49: 759–772.

    Article  CAS  PubMed  Google Scholar 

  32. Chamberlain MC, Kormanik PA. Prognostic significance of 111 indium-DTPA CSF flow studies in leptomeningeal metastasis.Neurology 1996;46: 1674–1677.

    Article  CAS  PubMed  Google Scholar 

  33. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases:111indium-DTPA CSF flow studies.Neurology 1991;41:1765–1769.

    Article  CAS  PubMed  Google Scholar 

  34. Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis. Clinical manifestations.Arch Neurol 1974;30: 138–143.

    Article  CAS  PubMed  Google Scholar 

  35. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study.Arch Neurol 1974;30: 122–137.

    Article  CAS  PubMed  Google Scholar 

  36. Theodore WH, Gendelman S. Meningeal carcinomatosis.Arch Neurol 1981;38: 696–699.

    Article  CAS  PubMed  Google Scholar 

  37. Houck JR, Murphy K. Sudden bilateral profound hearing loss resulting from meningeal carcinomatosis.Otolaryngol Head Neck Surg 1992;106: 92–97.

    Article  CAS  PubMed  Google Scholar 

  38. Civantos F, Choi YS, Applebaum EL. Meningeal carcinomatosis producing bilateral sudden hearing loss: a case report.Am J Otol 1992;13: 369–371.

    CAS  PubMed  Google Scholar 

  39. Julien Jet al. Primary meningeal B lymphoma presenting as a subacute ascending polyradiculoneuropathy.J Neurol Neurosurg Psychiatry 1991;54; 610–613.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Lossos A, Siegal T. Spinal subarachnoid hemorrhage associated with leptomeningeal metastases.J Neurooncol 1992;12: 167–171.

    Article  CAS  PubMed  Google Scholar 

  41. Dexter DD, Westmoreland BF, Cascino TL. Complex partial status epilepticus in a patient with leptomeningeal carcinomatosis.Neurology 1990;40: 858–859.

    Article  PubMed  Google Scholar 

  42. Kaplan JGet al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias.J Neurooncol 1990;9: 225–229.

    Article  CAS  PubMed  Google Scholar 

  43. Mahmoud HHet al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia.New Engl J Med 1993; 329: 314–319.

    Article  CAS  PubMed  Google Scholar 

  44. Lauer Set al. Prognostic significance of cerebrospinal fluid (CSF) lymphoblasts (LB) at diagnosis (dx) in children with acute lymphoblastic leukemia (ALL) [abstract].Proc Am Soc Clin Oncol 1994;13:317.

    Google Scholar 

  45. Gilchrist GSet al. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: a Children's Cancer Group reprot.J Clin Oncol 1994;12: 2594–2600.

    Article  CAS  PubMed  Google Scholar 

  46. Jaeckle KA, Krol G, Posner JB. Evolution of computed tomographic abnormalities in leptomeningeal metastases.Ann Neurol 1985;17: 85–89.

    Article  CAS  PubMed  Google Scholar 

  47. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain.Neurology 1990;40: 435–438.

    Article  CAS  PubMed  Google Scholar 

  48. Sze G. Diseases of the intracranial meninges: MR imaging features.AJR Am J Roentgenol 1993;160: 727–733.

    Article  CAS  PubMed  Google Scholar 

  49. Yousem DM, Patrone PM, Grossman RI. Leptomeningeal metastases: MR evaluation.J Comput Assist Tomogr 1990;14: 255–261.

    Article  CAS  PubMed  Google Scholar 

  50. Chamberlain MC. Comparative spine imaging in leptomeningeal metastases.J Neurooncol 1995;23: 233–238.

    Article  CAS  PubMed  Google Scholar 

  51. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using-111indium-DTPA ventriculography.Am J Med 1982;73: 641–647.

    Article  CAS  PubMed  Google Scholar 

  52. Glantz MJet al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status.Cancer 1995;75: 2919–2931.

    Article  CAS  PubMed  Google Scholar 

  53. Heideman R, Packer R, Albright L, Freeman C, Rorke L.Tumors of the Central Nervous System, vol 3. Philadelphia: Lippincott-Raven, 1997.

    Google Scholar 

  54. Grant R, Naylor B, Greenber H, Junck L. Clinical outcome in aggressively treated meningeal carcinomatosis.Arch Neurol 1994;51: 457–461

    Article  CAS  PubMed  Google Scholar 

  55. Fizazi Ket al. Meningeal carcinomatosis in patients with breast carcinoma.Cancer 1995;77: 1315–1323.

    Article  Google Scholar 

  56. Margolin J, Poplack D.Acute Lymphoblastic Leukemia, vol 3. Philadelphia: Lippincott-Raven, 1997.

    Google Scholar 

  57. Kun Let al. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia. I. Results of craniospinal irradiation.J Clin Oncol 1984;2: 359–364.

    Article  CAS  PubMed  Google Scholar 

  58. Freeman J, Johnston P, Voke J. Somnolence after prophylactic cranial irradiation in children with acute lymphoblastic leukemia.Br Med J 1973;4: 523–525.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Pratt Cet al. Second malignant neoplasms in survivors of acute childhood lymphocytic leukemia.Pediatr Res 1988;23: 862.

    Google Scholar 

  60. Voorhess MLet al. Hypothalamic-pituitary function of children with acute lymphocytic leukemia after three forms of central nervous system prophylaxis. A retrospective study.Cancer 1986;57: 1287–1291.

    Article  CAS  PubMed  Google Scholar 

  61. Pasqualini Tet al. Subtle primary hypothyroidism in patients treated for acute lymphoblastic leukemia.Acta Endocrinol (Copenh) 1991;124: 375–380.

    CAS  PubMed  Google Scholar 

  62. Blatt J, Bercu BB, Gillin JC, Mendelson WB, Poplack DG. Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia.J Pediatr 1984;104: 182–186.

    Article  CAS  PubMed  Google Scholar 

  63. Moss HA, Nannis ED, Poplack DG. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia.Am J Med 1981;71: 47–52.

    Article  CAS  PubMed  Google Scholar 

  64. Paolucci G, Rosito P.Adverse Sequelae of Central Nervous System Prophylaxis in Acute Lymphoblastic Leukemia. Boston: Martinus Nijhoff, 1983.

    Book  Google Scholar 

  65. Poplack D.Evaluation of Adverse Sequelae of Central Nervous System Prophylaxis in Acute Lymphoblastic Leukemia. Boston: Martinus Nijhoff, 1983.

    Book  Google Scholar 

  66. Balis F, Poplack D. Cancer chemotherapy. In: Nathan D, Oski F (eds),Hematology of Infancy and Childhood, 4th edn. Philadelphia: WB Saunders, 1993.

    Google Scholar 

  67. Blaney SM, Poplack DG. Pharmacologic strategies for the treatment of meningeal malignancy.Invest New Drugs 1996;14: 69–85.

    Article  CAS  PubMed  Google Scholar 

  68. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs.Am J Pediatr Hematol Oncol 1989;11: 74–86.

    Article  CAS  PubMed  Google Scholar 

  69. Collins J.Regional Therapy: An Overview. Boston: Martinus Nijhoff, 1987.

    Google Scholar 

  70. Larson S, Schall G, DiChiro G. The influence of previous lumbar puncture and pneumoencephalography.J Nucl Med 1981;12: 555–557.

    Google Scholar 

  71. Blaney SMet al. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration.J Clin Oncol 1995;13: 177–179.

    Article  CAS  PubMed  Google Scholar 

  72. Poplack D, Bleyer W, Horowitz M.Pharmacology of Antineoplastic Agents in Cerebrospinal Fluid, vol 2. New York: Plenum Press, 1980.

    Book  Google Scholar 

  73. Bleyer W: Clinical pharmacology of intrathecal methotrexate.Cancer Treat Rep 1977;61: 1419–1425.

    CAS  PubMed  Google Scholar 

  74. Bleyer WAet al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen.J Clin Oncol 1983;1: 317–325.

    Article  CAS  PubMed  Google Scholar 

  75. Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasmsCancer Treat Rep 1977;61: 733–743.

    CAS  PubMed  Google Scholar 

  76. Bleyer WAet al. The Ommaya reservoir: newly recognized complications and recommendations for insertion and use.Cancer 1978;41: 2431–2437.

    Article  CAS  PubMed  Google Scholar 

  77. Bleyer WA, Poplack DG, Simon RM. ‘Concentration— time’ methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms.Blood 1978;51: 835–842.

    Article  CAS  PubMed  Google Scholar 

  78. Kim Set al. Prolongation of drug exposure in cerebro-spinal fluid by encapsulation into DepoFoam.Cancer Res 1993;53: 1596–1598.

    CAS  PubMed  Google Scholar 

  79. Kim Set al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101.J Clin Oncol 1993;11: 2186–2193.

    Article  CAS  PubMed  Google Scholar 

  80. Glantz Jet al. A randomized trial of a slow-released formulation of cytarabine for the treatment of lymphomatous meningitis.J Clin Oncol 1999;17: 3110–3116.

    Article  CAS  PubMed  Google Scholar 

  81. Howell SB, Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W. A controlled trial of Depocyt for the treatment of lymphomatous meningitis.Proc Am Soc Clin Oncol 1999;18: 10a. Abstract No. 34

    Google Scholar 

  82. Glantz Met al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.Clin Cancer Res 1999;5: 3394–3402.

    CAS  PubMed  Google Scholar 

  83. Arndt CAet al. Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys.Cancer Res 1987;47: 5932–5934.

    CAS  PubMed  Google Scholar 

  84. Blaney SM, Poplack DG. New cytotoxic drugs for intrathecal administration.J Neurooncol 1998;38: 219–223.

    Article  CAS  PubMed  Google Scholar 

  85. Blaney Set al. A phase I study of intrathecal mafosfamide (MF) in patients with refractory meningeal malignancies [abstract].Proc Am Soc Clin Oncol 1992;11: 113.

    Google Scholar 

  86. Blaney Set al. Intrathecal administration of topotecan in nonhuman primates.Cancer Chemother Pharmacol 1995;36: 121–124.

    Article  CAS  PubMed  Google Scholar 

  87. Papanastassiou Vet al. Pharmacokinetics and dose estimates following intrathecal administration of131I-monoclonal antibodies for the treatment of central nervous system malignancies.Int J Radiat Oncol Biol Phys 1995;31: 541–552.

    Article  CAS  PubMed  Google Scholar 

  88. Pizer B, Kemshead J. The potential of targeted radiotherapy in the treatment of the central nervous system leukaemia.Leuk Lymphoma 1994;15: 281–289.

    Article  CAS  PubMed  Google Scholar 

  89. Gunther Ret al. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.Blood 1995;85: 2537–2545.

    Article  CAS  PubMed  Google Scholar 

  90. Mitani K, Graham F, Caskey C. Transduction of human bone marrow by adenoviral vector.Hum Gene Ther 1994;5: 941–948.

    Article  CAS  PubMed  Google Scholar 

  91. Lavery D, Fu S, Lufkin R, Chen-Kiang S. Productive infection of cultured human lymphoid cells by adenovirus.J Virol 1987;5: 1466–1472.

    Article  Google Scholar 

  92. Viola JJet al. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells.J Neurosurg 1995;82: 70–76.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology/Oncology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children's Cancer Center and Hematology Service, 6621 Fannin, MC 3-3320, 77030-2399, Houston, TX, USA

    SM Blaney

  2. Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA

    DG Poplack

  3. Department of Hematology-Oncology, Texas Children's Hospital, Houston, TX, USA

    DG Poplack

Authors
  1. SM Blaney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. DG Poplack
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to SM Blaney.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blaney, S., Poplack, D. Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol 17, 151–162 (2000). https://doi.org/10.1007/BF02780522

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02780522

Keywords

Search

Navigation